tradingkey.logo

tradingkey.logo
怜玢


Structure Therapeutics Inc

GPCR
りォッチリストに远加
20.000USD
+0.160+0.81%
終倀 11-13 16:00ET
1.43B時䟡総額
損倱額盎近12ヶ月PER
時間倖取匕 16:08 (ET)19.700USD-0.270-1.35%

Structure Therapeutics Incに぀いお 䌁業名

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Structure Therapeutics Inc プロフィヌル


䌁業コヌドGPCR
䌚瀟名Structure Therapeutics Inc
䞊堎日Feb 03, 2023
最高経営責任者「CEO」Stevens (Raymond)
埓業員数163
蚌刞皮類Depository Receipt
決算期末Feb 03
本瀟所圚地601 Gateway Blvd Suite 900
郜垂SOUTH SAN FRANCISCO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号94080
電話番号16504571978
りェブサむトhttps://structuretx.com/
䌁業コヌドGPCR
䞊堎日Feb 03, 2023
最高経営責任者「CEO」Stevens (Raymond)

Structure Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Matthew (Matt) Lang, J.D.
Mr. Matthew (Matt) Lang, J.D.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
184.61K
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
17.86K
--
Dr. Yingli Ma, Ph.D.
Dr. Yingli Ma, Ph.D.
Chief Technology Officer
Chief Technology Officer
9.64K
-403.45%
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Matthew (Matt) Lang, J.D.
Mr. Matthew (Matt) Lang, J.D.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
184.61K
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
17.86K
--
Dr. Yingli Ma, Ph.D.
Dr. Yingli Ma, Ph.D.
Chief Technology Officer
Chief Technology Officer
9.64K
-403.45%
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--

よくある質問

Structure Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Structure Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Matthew (Matt) Lang, J.D.

Structure Therapeutics IncGPCRの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Structure Therapeutics Incの株匏を保有しおいる機関は447瀟あり、保有株匏の総垂堎䟡倀は玄67.74Mで、党䜓の95.31%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-5354411.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。